Nuveen
CRNX

Nuveen’s Crinetics Pharmaceuticals CRNX Stock Holding History

Nuveen’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8M Buy
555,381
+3,917
+0.7% +$146K 0.01% 1239
2026
Q1 		$20M Buy
551,464
+28,998
+6% +$1.3M 0.01% 1140
2025
Q4 		$24.3M Sell
522,466
-22,288
-4% -$992K 0.01% 1033
2025
Q3 		$22.7M Buy
544,754
+19,803
+4% +$633K 0.01% 1070
2025
Q2 		$15.1M Sell
524,951
-37,984
-7% -$1.17M ﹤0.01% 1270
2025
Q1 		$15.9M Buy
562,935
+35,143
+7% +$1.31M ﹤0.01% 1271
2024
Q4 		$27M Buy
527,792
+13,598
+3% +$761K 0.01% 984
2024
Q3 		$26.3M Buy
514,194
+51,428
+11% +$2.65M 0.01% 998
2024
Q2 		$20.7M Sell
462,766
-90,973
-16% -$4.2M 0.01% 1106
2024
Q1 		$25.9M Sell
553,739
-125,432
-18% -$4.91M 0.01% 1012
2023
Q4 		$24.2M Buy
679,171
+268,230
+65% +$8.23M 0.01% 1032
2023
Q3 		$12.2M Buy
410,941
+67,762
+20% +$1.4M ﹤0.01% 1355
2023
Q2 		$6.18M Buy
343,179
+218,870
+176% +$4.36M ﹤0.01% 1797
2023
Q1 		$2M Sell
124,309
-13,384
-10% -$248K ﹤0.01% 2330
2022
Q4 		$2.52M Sell
137,693
-158,898
-54% -$2.8M ﹤0.01% 2280
2022
Q3 		$5.83M Sell
296,591
-105,419
-26% -$2.15M ﹤0.01% 1812
2022
Q2 		$7.5M Buy
402,010
+104,885
+35% +$2.09M ﹤0.01% 1696
2022
Q1 		$5.65M Buy
297,125
+1,613
+0.5% +$32.6K ﹤0.01% 1990
2021
Q4 		$7.16M Buy
295,512
+174,456
+144% +$4.3M ﹤0.01% 1889
2021
Q3 		$2.76M Sell
121,056
-27,293
-18% -$571K ﹤0.01% 2523
2021
Q2 		$2.8M Buy
148,349
+18,842
+15% +$331K ﹤0.01% 2549
2021
Q1 		$1.98M Sell
129,507
-7,655
-6% -$119K ﹤0.01% 2626
2020
Q4 		$1.94M Sell
137,162
-42,505
-24% -$592K ﹤0.01% 2526
2020
Q3 		$2.81M Buy
179,667
+23,095
+15% +$353K ﹤0.01% 2215
2020
Q2 		$2.74M Buy
156,572
+128,522
+458% +$2.19M ﹤0.01% 2200
2020
Q1 		$413K Sell
28,050
-191
-0.7% -$3.92K ﹤0.01% 2837
2019
Q4 		$709K Sell
28,241
-299
-1% -$5.69K ﹤0.01% 2806
2019
Q3 		$429K Sell
28,540
-1,166
-4% -$22.7K ﹤0.01% 2990
2019
Q2 		$742K Buy
+29,706
New +$736K ﹤0.01% 2865

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's CRNX Position: Q2 2026 in Review

Nuveen increased its Crinetics Pharmaceuticals (CRNX) stake by 0.71% in Q2 2026, buying an estimated $146K and bringing the position to 555,381 shares worth $20.8M. The position accounts for 0.01% of the portfolio, ranked #1239.

Nuveen first reported a position in CRNX in Q2 2019 and has held it in 29 quarters since. The position peaked at $27M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Nuveen held 555,381 shares of Crinetics Pharmaceuticals worth $20.8M as of Q2 2026.
  • Nuveen bought 3,917 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $146K.
  • Crinetics Pharmaceuticals made up 0.01% of Nuveen's portfolio in Q2 2026, its #1239 holding.
  • Nuveen first reported a position in Crinetics Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Crinetics Pharmaceuticals position peaked at $27M in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.